Abstract
AbstractMigraine headaches are a common neurological condition in children and adolescents. Frequent headaches can negatively impact a child's school attendance and leisure activities. Secondary effects can be disruptive to family dynamics with parental work absences and stress involved in caring for an ill child. Preventive therapies for pediatric migraine have not been well studied and reproducible data from clinical trials is notable for its paucity in the neurological literature. Antihistamines, B‐blockers, and other older therapies have limited data. Many of the newer therapies have been developed from anti‐epileptic drugs, which have reproducible safety data from pediatric epilepsy trials. This has generated further interest in evaluation of these newer agents such as topiramate and levetiracetam. However, for children and adolescents who will require preventive therapy to decrease migraine frequency; there is little evidence available for clinicians from randomized controlled trials. Drug Dev Res 68:350–354, 2007. © 2007 Wiley‐Liss, Inc.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
